Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 8/20 | 0.36 |
| ▸ | ERBB3 | P21860 | 7/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889118 | 0.80 | L3MBTL1 (0.44) | L3MBTL1EGFRERBB3SORT1LCK | |
| SCHEMBL16840694 | 0.75 | CYP1A2 (0.40) | L3MBTL1EGFRLCK | |
| SCHEMBL18185358 | 0.73 | L3MBTL1 (0.48) | L3MBTL1EGFRERBB3SORT1LCK | |
| SCHEMBL374583 | 0.73 | L3MBTL1 (0.59) | L3MBTL1EGFRERBB3SORT1 | |
| SCHEMBL18787026 | 0.73 | L3MBTL1 (0.84) | L3MBTL1EGFRERBB3SORT1RIPK1 | |
| SCHEMBL11326441 | 0.72 | CCR1 (0.36) | — | |
| SCHEMBL19489281 | 0.72 | EGFR (0.48) | EGFR | |
| SCHEMBL792949 | 0.70 | L3MBTL1 (0.46) | L3MBTL1EGFRERBB3SORT1SMN1; SMN2 | |
| SCHEMBL5913167 | 0.69 | NR3C2 (0.53) | LOXL2 | |
| SCHEMBL16513679 | 0.69 | L3MBTL1 (0.48) | L3MBTL1SORT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8697708-B2 | Azabenzothiazole compounds, compositions and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-15 | — | — | US | disclosed |
| EP-2616072-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| CN-103209695-A | Azabenzothiazole compounds, compositions and methods of use | HOFFMANN LA ROCHE | 2013-07-17 | — | — | CN | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | L3MBTL1 3602/4885EGFR 2436/4885ERBB3 2318/4885 |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | L3MBTL1 3602/4885EGFR 2436/4885ERBB3 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.